A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation
Advanced Melanoma
DRUG: HLX208
ORR, Objective response rate(assessed by independent radiological review committee (IRRC) based on the e RECIST Version 1.1), from first dose to the last patient was followed up for 6 month
PFS, Progression-free survival(PFS):assessed by IRRC and the investigator based on the RECIST Version 1.1, from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier)，assessed up to 1 years|DOR, Duration of response, from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first) assessed up to 1 years|OS, Overall survival, from the first dose to the time of death due to any cause，assessed up to 2 years
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation